Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171,717,172
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
126,709,981
-
Shares change
-
-1,943,486
-
Total reported value, excl. options
-
$826,133,526
-
Value change
-
-$18,822,117
-
Put/Call ratio
-
10.59%
-
Number of buys
-
92
-
Number of sells
-
-74
-
Price
-
$6.52
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q2 2024
203 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 126,709,981 shares
of 171,717,172 outstanding shares and own 73.79% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27,904,963 shares), VANGUARD GROUP INC (11,704,866 shares), BlackRock Inc. (10,542,667 shares), Casdin Capital, LLC (8,448,574 shares), Bellevue Group AG (6,377,115 shares), PRICE T ROWE ASSOCIATES INC /MD/ (5,039,015 shares), STATE STREET CORP (4,248,406 shares), JPMORGAN CHASE & CO (3,963,401 shares), Nextech Invest Ltd. (3,846,409 shares), and NORGES BANK (3,319,342 shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.